Literature DB >> 7559538

In vitro processing of human tumor necrosis factor-alpha.

S Robache-Gallea1, V Morand, J M Bruneau, B Schoot, E Tagat, E Réalo, S Chouaib, S Roman-Roman.   

Abstract

Tumor necrosis factor (TNF)-alpha is initially synthesized as a membrane-bound, cell-associated 26-kDa protein that is further cleaved to yield the soluble 17-kDa form. By using a radiolabeled in vitro translated TNF-alpha precursor we detected a serine proteinase processing activity present in crude membrane preparations of monocytic cells able to generate a 17-kDa active protein. A similar processing pattern was obtained using purified neutral serine proteinase proteinase-3 (PR-3). Moreover, while a secretory leukocyte proteinase inhibitor (a natural serine anti-proteinase) did not affect the in vitro TNF-alpha processing, IgG preparations containing high titers of anti-PR-3 autoantibodies completely blocked this activity. The NH2-terminal sequencing of the reaction products obtained with either membrane preparations or PR-3 showed that cleavage occurs in both cases between Val77 and Arg78. These results together with cellular expression and localization of PR-3 suggest a potential role for this enzyme as an accessory TNF-alpha processing enzyme.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559538     DOI: 10.1074/jbc.270.40.23688

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Molecular and cellular mechanisms of ectodomain shedding.

Authors:  Kazutaka Hayashida; Allison H Bartlett; Ye Chen; Pyong Woo Park
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

3.  Contradictory functions (activation/termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity.

Authors:  Suyoung Bae; Taebong Kang; Jaewoo Hong; Siyoung Lee; Jida Choi; Hyunjhung Jhun; Areum Kwak; Kwangwon Hong; Eunsom Kim; Seunghyun Jo; Soohyun Kim
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

Review 4.  Neutrophil serine proteases fine-tune the inflammatory response.

Authors:  Christine T N Pham
Journal:  Int J Biochem Cell Biol       Date:  2007-11-29       Impact factor: 5.085

Review 5.  Membrane protein secretases.

Authors:  N M Hooper; E H Karran; A J Turner
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

6.  Inter-alpha inhibitor protein administration improves survival from neonatal sepsis in mice.

Authors:  Kultar Singh; Ling Xiu Zhang; Kreso Bendelja; Ryan Heath; Shaun Murphy; Surendra Sharma; James F Padbury; Yow-Pin Lim
Journal:  Pediatr Res       Date:  2010-09       Impact factor: 3.756

7.  Relationship between the increase of secretion of sTNF alpha induced by lipopolysaccharides and the enhanced expression of TACE mRNA in HL-60 cells and adhesive cells from human spleen.

Authors:  T Ding; L Li; K Zhu; W Huang; Y Yang
Journal:  J Tongji Med Univ       Date:  2001

8.  A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide.

Authors:  J Sun; D N Fass; M A Viss; A M Hummel; H Tang; H A Homburger; U Specks
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  Proteinase 3 and prognosis of patients with acute myocardial infarction.

Authors:  Leong L Ng; Sohail Q Khan; Hafid Narayan; Paulene Quinn; Iain B Squire; Joan E Davies
Journal:  Clin Sci (Lond)       Date:  2011-03       Impact factor: 6.124

10.  Proteinase 3 is an IL-32 binding protein.

Authors:  Daniela Novick; Menachem Rubinstein; Tania Azam; Aharon Rabinkov; Charles A Dinarello; Soo-Hyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.